





















- omized, placebo-controlled phase III clinical trial of  $\beta$ -d-mannuronic acid in rheumatoid arthritis patients. *Inflammopharmacology*. 2018 [Epub ahead of print].
40. Mirshafiey A, Cuzzocrea S, Rehm B, et al. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. *Scand J Immunol*. 2005; 61: 435-41.
  41. Mirshafiey A, Cuzzocrea S, Rehm BH, Matsuo H. M2000: a revolution in pharmacology. *Med Sci Monit*. 2005; 11: Pi53-Pi63.
  42. Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. *Immunopharmacol Immunotoxicol*. 2005; 27: 255-65.
  43. Mirshafiey A, Rehm B, Cuzzocrea S, et al. M2000, foundation of a new generation among NSAIDs. *Lett Drug Des Discov*. 2005; 2: 412-23.
  44. Lipsky PE. Are new agents needed to treat RA? *Nat Rev Rheumatol*. 2009; 5: 521-2.
  45. van Steenberg HW, da Silva JAP, Huizinga TWJ, van der Helm-van Mil AHM. Preventing progression from arthralgia to arthritis: targeting the right patients. *Nature reviews. Rheumatology*. 2005; 14: 32-41,
  46. Buckley F, Finckh A, Huizinga TWJ, et al. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. *J Manag Care Spec Pharm*. 2015; 21: 409-23.
  47. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. *J Exp Med*. 1995; 182: 1825-31.
  48. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. *J Clin Invest*. 2001; 108: 1781-8.
  49. Kasperkivits PV, Verbeet NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. *Ann Rheum Dis*. 2004; 63: 273-9.
  50. Jones GW, Greenhill CJ, Williams JO, et al. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. *Ann Rheum Dis*. 2013; 72: 1738-42.

Non-commercial use only